首页> 外文OA文献 >Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials

【2h】

Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials

机译：双层含有Lapatinib和Trastuzumab的双粒子与单孕曲妥珠单抗相结合化疗，作为HER2阳性乳腺癌的Neoadjuvant治疗：随机试验的荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Matteo Clavarezza; Matteo Puntoni; Alessandra Gennari; Laura Paleari; Nicoletta Provinciali; Mauro DAmico; Andrea DeCensi;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials [J] . Clavarezza Matteo, Puntoni Matteo, Gennari Alessandra, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第18期

机译：拉帕替尼和曲妥珠单抗与单药曲妥珠单抗联合化疗联合化疗作为HER2阳性乳腺癌新辅助治疗的随机对照试验的荟萃分析
2. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. [J] . Gianni L, Eiermann W, Semiglazov V, The Lancet . 2010,第9712期

机译：对于HER2阳性的局部晚期乳腺癌患者，使用曲妥珠单抗的新辅助化疗联合曲妥珠单抗辅助与单独的新辅助化疗相比（NOAH试验）：一项平行HER2阴性队列的随机对照优势试验。
3. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials [J] . Solinas C., Ceppi M., Lambertini M., Cancer Treatment Reviews . 2017,第期

机译：用Neoadjuvant化疗加上rrastuzumab，Lapatinib或它们的组合治疗Her2阳性乳腺癌患者的肿瘤浸润淋巴细胞：随机对照试验的荟萃分析
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
6. A randomized controlled phase II trial of neoadjuvant ado-trastuzumab emtansine lapatinib and nab-paclitaxel versus trastuzumab pertuzumab and paclitaxel in HER2-positive breast cancer (TEAL study) [O] . Tejal A. Patel, Joe E. Ensor, Sarah L. Creamer, 2019

机译：HER2阳性乳腺癌的新辅助药物阿托曲妥珠单抗坦帕尼和纳布-紫杉醇与曲妥珠单抗帕妥珠单抗和紫杉醇的II期随机对照对照试验（TEAL研究）
7. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer [O] . Guarneri, Valentina, Dieci, Maria Vittoria, Frassoldati, Antonio, 2015

机译：随机CHER-LOB研究的前瞻性生物标志物分析，评估曲妥珠单抗和拉帕替尼联合化学疗法作为HER2阳性乳腺癌新辅助疗法的双重抗HER2治疗

Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials

著录项

引文网络

相似文献

相关主题

期刊订阅